Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Bremelanotide Acetate
Therapeutic Area : Undisclosed
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
March 10, 2025
Lead Product(s) : Bremelanotide Acetate
Therapeutic Area : Undisclosed
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Segesterone Acetate,Ethinyl Estradiol
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Approved FDF
Recipient : Mayne Pharma
Deal Size : $430.0 million
Deal Type : Acquisition
Cosette Pharmaceuticals Acquires Mayne Pharma for Women’s Health Leadership
Details : Through the acquisition, Cosette will utilize market-leading commercial products focused on women’s health, including Annovera (segesterone acetate & ethinyl estradiol) to prevent preganancy.
Product Name : Annovera
Product Type : Steroid
Upfront Cash : Undisclosed
February 20, 2025
Lead Product(s) : Segesterone Acetate,Ethinyl Estradiol
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Approved FDF
Recipient : Mayne Pharma
Deal Size : $430.0 million
Deal Type : Acquisition
Lead Product(s) : Zolpidem Tartrate
Therapeutic Area : Sleep
Study Phase : Approved FDF
Recipient : Sanofi
Deal Size : Undisclosed
Deal Type : Acquisition
Cosette Acquires Ambien® and Ambien CR® from Sanofi US
Details : Cosette Pharmaceuticals Acquires Ambien (Zolpidem Tartrate) Tablet from Sanofi US. It is indicated for the short-term treatment of insomnia characterized by difficulties with sleep initiation.
Product Name : Ambien
Product Type : Controlled Substance
Upfront Cash : Undisclosed
October 07, 2024
Lead Product(s) : Zolpidem Tartrate
Therapeutic Area : Sleep
Highest Development Status : Approved FDF
Recipient : Sanofi
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Bremelanotide Acetate
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved FDF
Recipient : Palatin Technologies
Deal Size : $171.0 million
Deal Type : Acquisition
Cosette Pharmaceuticals Acquires Vyleesi® from Palatin Technologies
Details : Cosette expands its women's health platform by acquiring Vyleesi (bremelanotide acetate), first as-needed treatment for premenopausal women with acquired generalized hypoactive sexual desire disorder.
Product Name : Vyleesi
Product Type : Peptide
Upfront Cash : $12.0 million
March 01, 2024
Lead Product(s) : Bremelanotide Acetate
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Recipient : Palatin Technologies
Deal Size : $171.0 million
Deal Type : Acquisition
Lead Product(s) : Nitroglycerin
Therapeutic Area : Gastroenterology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Cosette Pharmaceuticals Announces Approval and Launch Of First Generic Rectiv®
Details : Rectiv-Generic (nitroglycerin) is a nitrate vasodilator activating guanylate cyclase to increase cyclic GMP in smooth muscle. It is indicated for treating moderate to severe chronic anal fissure pain.
Product Name : Rectiv-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 22, 2024
Lead Product(s) : Nitroglycerin
Therapeutic Area : Gastroenterology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Bremelanotide Acetate
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved FDF
Recipient : Palatin Technologies
Deal Size : $171.0 million
Deal Type : Divestment
Palatin Completes Sale of Vyleesi to Cosette Pharmaceuticals for up to $171 mn
Details : Cosette expands its women's health platform through divestment by adding Vyleesi, the first approved as-needed treatment for premenopausal women with acquired hypoactive sexual desire disorder.
Product Name : Vyleesi
Product Type : Peptide
Upfront Cash : $12.0 million
February 01, 2024
Lead Product(s) : Bremelanotide Acetate
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Recipient : Palatin Technologies
Deal Size : $171.0 million
Deal Type : Divestment
Lead Product(s) : Bremelanotide Acetate
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved FDF
Recipient : Palatin Technologies
Deal Size : $171.0 million
Deal Type : Divestment
Palatin Completes Sale of Vyleesi® to Cosette Pharmaceuticals for up to $171 Million
Details : Through the divestment, Cosette will further expand its women's health platform by adding Vyleesi (bremelanotide acetate), the first and only as-needed treatment approved for premenopausal women with acquired, generalized hypoactive sexual desire disorde...
Product Name : Vyleesi
Product Type : Peptide
Upfront Cash : $12.0 million
December 20, 2023
Lead Product(s) : Bremelanotide Acetate
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Recipient : Palatin Technologies
Deal Size : $171.0 million
Deal Type : Divestment
Lead Product(s) : Metronidazole
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Cosette Pharmaceuticals Announces the Approval and Launch of Metronidazole Gel USP, 1%
Details : Metronidazole diffuses into the organism, inhibits protein synthesis by interacting with DNA, and causes a loss of helical DNA structure and strand breakage. Therefore, it causes cell death in susceptible organisms.
Product Name : Dapsone
Product Type : Plant Extract/Herbal
Upfront Cash : Inapplicable
September 02, 2023
Lead Product(s) : Metronidazole
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Prasterone
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Approved FDF
Recipient : Endoceutics
Deal Size : Undisclosed
Deal Type : Acquisition
Cosette Pharmaceuticals Acquires Intrarosa® from Endoceutics, Inc.
Details : The acquisition accelerates Cosette’s women’s health portfolio, with a differentiated, commercial stage, patent protected product, Intrarosa (prasterone), the only prescription drug providing both estrogen and androgen for the treatment of moderate-t...
Product Name : Intrarosa
Product Type : Hormone
Upfront Cash : Undisclosed
August 06, 2023
Lead Product(s) : Prasterone
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Approved FDF
Recipient : Endoceutics
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Metronidazole
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Dapsone (metronidazole) is a vaginal gel, generic version of MetroGel-Vaginal by Bausch Health, and is indicated for the topical treatment of inflammatory lesions of rosacea.
Product Name : Dapsone
Product Type : Plant Extract/Herbal
Upfront Cash : Inapplicable
July 27, 2023
Lead Product(s) : Metronidazole
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable